Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil
Status:
Recruiting
Trial end date:
2023-02-02
Target enrollment:
Participant gender:
Summary
Randomized controlled parallel open-label study in persons living with HIV. The aim is to
study weight changes in patients switching from a dolutegravir and tenofovir disoproxil
containing regimen to either a dolutegravir or tenofovir disoproxil free regimen.